Fresenius lays out its strategy, shares sit in the DAX healthcare cohort

Fresenius presents itself as a diversified healthcare group with exposure to hospitals, generics and medical services. Investors look at the long-term strategy and DAX membership when assessing the shares.

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-29, 14:47.

Fresenius SE & Co. KGaA (DE0005785604) is one of Germany's established healthcare groups, listed in the DAX and trading on Xetra under the symbol FRE. The company positions itself as a diversified provider of hospital services, generic pharmaceuticals and medical-care solutions according to its corporate information.

How Fresenius is set up

Fresenius combines several operating platforms under one umbrella, including Helios hospitals, Kabi intravenous generics and nutrition products, and the separately listed Fresenius Medical Care dialysis group. This mix gives the stock exposure to both regulated hospital reimbursement and global off-patent drug markets.

The group employs more than 170,000 people worldwide and traces its roots back to 1912 as a pharmacy business in Frankfurt, as Fresenius highlights in its company overview. The current legal structure as a Kommanditgesellschaft auf Aktien reflects a long-standing German corporate tradition.

Where analysts place Fresenius

On the US OTC market, the Fresenius SE & Co. FSNUY shares trade at around 11.41 dollars, giving a market capitalization of about 25.7 billion dollars and a trailing price-earnings ratio of 15.2, MarketBeat calculates as of the latest closing data. The forward P/E is lower at roughly 11.1, pointing to expectations of earnings growth.

MarketBeat also notes a dividend yield near 1.75 percent for the FSNUY line, with consensus data there showing a Buy rating for the Fresenius equity. This US quotation offers international investors an additional way to access the group alongside the primary Xetra listing.

The business behind the stock

Fresenius earns most of its revenue from healthcare services and products, with Helios hospitals treating patients across Europe and Latin America and Kabi supplying intravenous generics, biosimilars and clinical nutrition. The group also holds a major stake in Fresenius Medical Care, which operates dialysis clinics worldwide.

This diversified business model ties Fresenius closely to demographic trends such as aging populations and chronic diseases, underpinning demand for hospital capacity, kidney dialysis and injectable pharmaceuticals. Regulatory frameworks and reimbursement systems in Europe and the Americas are central to the group's profitability.

Where the shares trade today

The Fresenius shares (DE0005785604) trade in Germany on Xetra under the symbol FRE, with the latest available quote around 39.9 euros according to recent Frankfurt data, placing the company firmly in the DAX healthcare segment.

Key data on the Fresenius shares

• Company: Fresenius SE & Co. KGaA
• ISIN: DE0005785604
• WKN: 578560
• Ticker: FRE
• Trading venue: Xetra
• Price (as of 2026-06-29, 14:30): 39.90 EUR
• Market cap: 25.71 billion USD (as of 2026-06-26)
• Sector / industry: Health Care Providers & Services
• Index membership: DAX
• Next earnings date: not officially scheduled

Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation or a solicitation to buy or sell any securities. All data are based on sources cited and may change without notice.